Ekso Bionics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
July 28, 2022 at 05:12 pm
Share
Ekso Bionics Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 3.47 million compared to USD 2.21 million a year ago. Net loss was USD 2.98 million compared to USD 1.27 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.1 a year ago. Diluted loss per share from continuing operations was USD 0.23 compared to USD 0.11 a year ago.
For the six months, sales was USD 6.03 million compared to USD 4.12 million a year ago. Net loss was USD 7.6 million compared to USD 4.94 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to USD 0.44 a year ago.
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.